Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 872

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Prostate cancer

Not recruiting

Study on High-Intensity Focused Ultrasound and Leuprorelin Acetate for Intermediate Risk Prostate Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate

Bladder cancer

Not recruiting

Study of Sasanlimab and Sacituzumab Govitecan for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab

Soft tissue sarcoma

Not recruiting

Study of Bintrafusp Alfa and Doxorubicin Hydrochloride for Adults with Advanced Soft-Tissue Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bintrafusp Alfa

Renal cancer+4

Not recruiting

Study on the Effectiveness of Atezolizumab with Radiotherapy for Patients with Metastatic Colorectal, Lung, Renal, and Sarcoma Cancers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study on the Effectiveness of Sodium Chloride and Sodium Citrate in Intensive Care Patients Undergoing Continuous Kidney Purification

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Study on Rivaroxaban for Stabilizing Carotid Artery Plaques in Patients with Stable Peripheral Artery Disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban

Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Romidepsin

B-cell lymphoma

Not recruiting

Study of Acalabrutinib Alone or with Rituximab for Patients with Relapsed/Refractory Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Study of Pembrolizumab and Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study of Durvalumab and Regorafenib for Patients with Stage IV Colorectal Cancer with No Evidence of Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Study on Cabozantinib for Patients with Liver Cancer Not Responding to Previous Immune Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.